11 recruiting, 6 unknown, 2 active not recruiting, 2 completed. 23 Phase 2, 12 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 23 | Recruiting 11, Unknown 6, Active not recruiting 2, Completed 2, Terminated 2 |
| Phase 1 | 12 | Recruiting 7, Completed 2, Active not recruiting 1, Terminated 1, Unknown 1 |
Follow Refractory Cancer: new trials by email Literature Review of Refractory Cancer trials Research Report on Refractory Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Investigate Safety and Effectiveness of Tacabrutideg (BGB-16673) in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies Tacabrutideg, Sonrotoclax, Zanubrutinib - B-cell Malignancy, Relapsed Cancer | Phase 1 / Phase 2 | Recruiting | BeOne Medicines | 80 | 2024-11-27 | 2026-09-11 |
| Optimal Precision TherapIes to CustoMISE Care in Childhood and Adolescent Cancer Paxalisib, Opdualag, Irinotecan (drug) - Childhood Cancer, Childhood Solid Tumor | Phase 1 / Phase 2 | Recruiting | Australian & New Zealand Children's Haematology/Oncology Group | 90 | 2024-07-10 | 2026-01-28 |
| Zanubrutinib With Pemetrexed to Treat Relapsed/Refractory Primary and Secondary Central Nervous System (CNS) Lymphomas Pemetrexed, Zanubrutinib, Autologous Stem Cell Transplant (ASCT) - Primary Central Nervous System Lymphoma, Secondary Central Nervous System Lymphoma | Phase 2 | Recruiting | Baptist Health South Florida | 15 | 2024-04-25 | 2026-03-03 |
| A Dose Escalation and Expansion Study of [177Lu]Lu-SN201 in Participants With Advanced Cancer [177Lu]Lu-SN201 - Solid Tumor, Metastatic Cancer | Phase 1 / Phase 2 | Recruiting | Spago Nanomedical AB | 90 | 2023-12-06 | 2025-11-20 |
| Safety and Efficacy of Epcoritamab With Gemcitabine, Dexamethasone, and Cisplatin (GDP) Salvage Chemotherapy in Relapsed Refractory Large B-cell Lymphoma AutoSCT OR CAR T-cell Therapy, GDP, Epcoritamab - Large Cell Lymphoma, Diffuse, Relapsed Cancer | Phase 2 | Recruiting | Vijendra Singh | 35 | 2023-10-31 | 2026-11-05 |
| Leflunomide or Combination of MEK Inhibitor and Hydroxychloroquine for Refractory Patients With RAS Mutations Leflunomide, The combination of MEK inhibitor + hydroxychloroquine( plaquenil) ± bevacizumab - RAS Mutation, Ras (Kras or Nras) Gene Mutation | Phase 2 | Unknown | N.N. Petrov National Medical Research Center of Oncology | 20 | 2023-10-03 | 2024-01-29 |
| IMA402 T Cell-Engaging Receptor Molecule (TCER®) in Recurrent and/or Refractory Solid Tumors IMA402, IMA402 and checkpoint inhibitor, IMA402 and chemotherapy - Refractory Cancer, Recurrent Cancer | Phase 1 / Phase 2 | Recruiting | Immatics Biotechnologies GmbH | 400 | 2023-08-09 | 2026-09-01 |
| A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors SNS-101 (anti-VISTA), Cemiplimab - Solid Tumor, Adult, Advanced Solid Tumor | Phase 1 / Phase 2 | Completed | Sensei Biotherapeutics, Inc. | 98 | 2023-05-31 | 2026-09-02 |
| A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies GV20-0251, GV20-0251 and Pembrolizumab [KEYTRUDA®] - Solid Tumor, Adult, Refractory Cancer | Phase 1 / Phase 2 | Recruiting | GV20 Therapeutics | 365 | 2023-03-23 | 2025-02-13 |
| A Study of HST-1011 Given as Monotherapy and in Combination With an Anti-PD1 Antibody HST-1011, Cemiplimab - Solid Tumor, Adult, Relapsed Cancer | Phase 1 / Phase 2 | Active not recruiting | HotSpot Therapeutics, Inc | 77 | 2023-03-15 | 2025-02-04 |
| Study of Pembrolizumab With Bendamustine in Hodgkin Lymphoma Pembrolizumab, Bendamustine Hydrochloride - Classical Hodgkin Lymphoma, Relapsed Cancer | Phase 2 | Recruiting | University Health Network, Toronto | 40 | 2021-12-20 | 2026-06-23 |
| Efficacy and Safety of PVT-1 Treatment in Patients With Advanced Non-Small Cell Lung Cancer PVT-1 - Non Small Cell Lung Cancer, Advanced Cancer | Phase 2 | Unknown | PlusVitech S.L. | 24 | 2021-03-10 | 2023-04-05 |
| Fatty Acid Synthase Inhibition in Castration Refractory Prostate Cancer Omeprazole 80 mg twice daily - Prostate Cancer, Refractory Cancer | Phase 2 | Recruiting | Wake Forest University Health Sciences | 50 | 2021-03-05 | 2026-04-13 |
| Study of TBX-3400 in Subjects With Solid Malignant Tumors Resistant or Refractory to Standard Therapies TBX-3400 - Cancer, Tumor, Solid | Phase 1 / Phase 2 | Unknown | Taiga Biotechnologies, Inc. | 60 | 2021-01-25 | 2022-02-02 |
| Arsenic Trioxide for Structural p53 Mutations Arsenic Trioxide - Arsenic Trioxide, p53 Mutations | Phase 2 | Unknown | Shanghai Changzheng Hospital | 30 | 2021-01-01 | 2021-01-06 |
| Study of Enasidenib and Venetoclax in IDH2-Mutated Blood Cancers Enasidenib, Venetoclax - Acute Myeloid Leukemia, Relapsed Cancer | Phase 1 / Phase 2 | Terminated | University Health Network, Toronto | 27 | 2020-11-05 | 2024-01-24 |
| Pembrolizumab, Ibrutinib and Rituximab in PCNSL Ibrutinib, Pembrolizumab, Rituximab - Primary Central Nervous System Lymphoma, Recurrent Cancer | Phase 1 / Phase 2 | Recruiting | Dana-Farber Cancer Institute | 37 | 2020-08-01 | 2026-10-21 |
| ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors IMA203 Product, IMA203 product- flat dose, IMA203CD8 Product - Refractory Cancer, Recurrent Cancer | Phase 1 / Phase 2 | Recruiting | Immatics US, Inc. | 375 | 2019-05-14 | 2026-05-13 |
| 9-ING-41 in Patients With Advanced Cancers 9-ING-41, Gemcitabine - 21 day cycle, Doxorubicin. - Cancer, Pancreatic Cancer | Phase 2 | Active not recruiting | Actuate Therapeutics Inc. | 350 | 2019-01-04 | 2026-04-03 |
| A Phase I/II Study of Pexa-Vec Oncolytic Virus in Combination With Immune Checkpoint Inhibition in Refractory Colorectal Cancer Durvalumab, Tremelimumab, Pexa-Vec - Colorectal Cancer, Colorectal Carcinoma | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 34 | 2017-12-07 | 2023-10-24 |
Showing 20 of 23. Sign in to see all of them.
Neoplasms (23) · Recurrence (11) · Melanoma (4) · Carcinoma, Non-Small-Cell Lung (3) · Colorectal Neoplasms (3) · Neoplasm Metastasis (3) · Pancreatic Neoplasms (3) · Prostatic Neoplasms (3) · Breast Neoplasms (2) · Kidney Neoplasms (2) · Lung Neoplasms (2) · Lymphoma, Large B-Cell, Diffuse (2) · Ovarian Neoplasms (2) · Sarcoma (2) · Thyroid Neoplasms (2)
Pathologic Processes (14) · Pathological Conditions, Signs and Symptoms (14) · Disease Attributes (11) · Neoplasms by Site (11) · Neoplasms by Histologic Type (10) · Hemic and Lymphatic Diseases (6) · Urogenital Diseases (6) · Urogenital Neoplasms (6) · Endocrine Gland Neoplasms (5) · Endocrine System Diseases (5) · Genital Diseases (5) · Immune System Diseases (5) · Immunoproliferative Disorders (5) · Lung Diseases (5) · Lymphatic Diseases (5)
pembrolizumab (3) · Bendamustine Hydrochloride (2) · Irinotecan (2) · Rituximab (2) · cemiplimab (2) · ibrutinib (2) · zanubrutinib (2) · 3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione (1) · Afatinib (1) · Albumin-Bound Paclitaxel (1) · Antibodies, Monoclonal (1) · Arsenic (1) · Arsenic Trioxide (1) · Automobiles (1) · Bevacizumab (1)
University Health Network, Toronto (2) · Actuate Therapeutics Inc. (1) · Australian & New Zealand Children's Haematology/Oncology Group (1) · Baptist Health South Florida (1) · BeOne Medicines (1) · Chinese Academy of Medical Sciences (1) · Dana-Farber Cancer Institute (1) · GV20 Therapeutics (1) · HotSpot Therapeutics, Inc (1) · Immatics Biotechnologies GmbH (1) · Immatics US, Inc. (1) · Meirav Kedmi MD (1) · N.N. Petrov National Medical Research Center of Oncology (1) · National Cancer Institute (NCI) (1) · PlusVitech S.L. (1)
United States (12) · Canada (5) · Germany (4) · Australia (3) · China (3) · Israel (2) · Netherlands (2) · Spain (2) · Belgium (1) · Brazil (1) · France (1) · Italy (1) · New Zealand (1) · Poland (1) · Portugal (1)
Alison O'Neill, MD (1) · Cedrik Britten, M.D. (1) · Daniel Morgenstern, Dr (1) · David Ziegler, Prof (1) · Evgeny Imyanitov (1) · John Kuruvilla, M.D. (1) · Kim Taubman (1) · Lakshmi Nayak, MD (1) · Michael Goodman, MD (1) · Ron Weitzman, MD (1) · Sahin Lacin (1) · Steven Chan, M.D. (1)
PMID 20179235, PMID 24327518, PMID 27424289, PMID 28053024, PMID 28672195, PMID 29383130, PMID 29846250, PMID 30405781, PMID 30975030, PMID 31101621, PMID 31401903, PMID 31533931, PMID 31831767, PMID 31882719, PMID 31894292, PMID 35417717, PMID 35815408, PMID 36754451, PMID 39572395, PMID 40205198, PMID 41075807, PMID 41981308
P30CA012197 (1)